The concurrent diagnosis of a KRAS-driven PRNRP and a TSC/mTOR pathway-associated RCC-FMS, accompanied by an adrenal adenoma, forms a distinctive clinical scenario. This evidence concerns the gene KRAS and renal cell carcinoma.